There is a significant need for new antibiotics to treat serious drug-resistant gram-positive infections. By far the most prevalent drug-resistant gram-positive bacterium in the hospital and community today methicillin-resistant Staphylococcus aureus, or MRSA. MRSA infections have created an increasing burden on healthcare resources, thereby driving the need for new treatments that improve patient outcomes and reduce the cost of healthcare. The market for antibiotics labeled for MRSA is growing rapidly. The total United States sales for the five antibiotics labeled for MRSA grew from $778 million in 2005 to $1.5 billion in 2009.